Clinical Trial Update: Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating HBI-8000 in Japanese patients with Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• HBI-8000

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED